Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  The Lancet

• Publication date

  2003-09-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(03)14361-9PMID 14511925
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck.

  2004cited by this paper
• Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology.

  2003cited by this paper
• Targeting epidermal growth factor receptor--are we missing the mark?

  2003cited by this paper
• Management and outcome differences in supraglottic cancer between Ontario, Canada, and the Surveillance, Epidemiology, and End Results areas of the United States.

  2003cited by this paper
• Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.

  2003cited by this paper
• A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1 week shortening overall time.

  2002cited by this paper
• ARCON: a novel biology-based approach in radiotherapy.

  2002cited by this paper
• Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

  2002cited by this paper
• A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study.

  2002cited by this paper
• Radiotherapy for cancer of the head and neck: altered fractionation regimens.

  2002cited by this paper
• Conventional vs modified fractionated radiotherapy. meta-analysis of radiotherapy in head & neck squamous cell carcinoma : a meta-analysis based on individual patient data

  2002cited by this paper
• Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

  2001cited by this paper
• A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.

  2000cited by this paper
• Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity.

  2000cited by this paper
• Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers.

  2000cited by this paper
• Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data

  2000cited by this paper
• Importance of overall treatment time for the response to radiotherapy in patients with squamous cell carcinoma of the head and neck.

  2000cited by this paper
• Very accelerated versus conventional radiotherapy in HNSCC: Results of the GORTEC 94-02 randomized trial

  2000cited by this paper
• A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003

  1999cited by this paper
• Benefits of accelerated hyperfractionation for head and neck cancer.

  1999cited by this paper
• A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.

  1998cited by this paper
• A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer.

  1997cited by this paper
• Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial.

  1997cited by this paper
• Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation.

  1997cited by this paper
• A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer.

  1997cited by this paper
• Modification of Hypoxia-Induced Radioresistance in Tumors by the Use of Oxygen and Sensitizers.

  1996cited by this paper
• The Role of Altered Fractionation in Head and Neck Cancers.

  1992cited by this paper
• Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy.

  1992cited by this paper
• Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study.

  1989cited by this paper
• The hazard of accelerated tumor clonogen repopulation during radiotherapy.

  1988cited by this paper
• Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx.

  1988cited by this paper
• Primary radiotherapy of larynx and pharynx carcinoma--an analysis of some factors influencing local control and survival.

  1986cited by this paper

• Hypofractionated Versus Normofractionated Accelerated Radiation Therapy With or Without Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma (HYPNO): A Randomized, Open-Label, Phase 3, Noninferiority Trial.

  2026cites this paper
• An international placebo-controlled randomized multicenter trial of nimorazole with accelerated chemo-radiotherapy for locally advanced HPV-negative squamous cell carcinoma of the head and neck (HNSCC).

  2025cites this paper
• Transfusion thresholds and other strategies for guiding red blood cell transfusion.

  2025cites this paper
• Comparative study between single modality radiotherapy and concurrent chemoradiation for selected patients with early-stage laryngeal cancer.

  2025cites this paper
• A Prospective Randomized Study to Assess the Feasibility and Compare the Acute Toxicity and Early Treatment Response in Locally Advanced Head-and-neck Patients Treated with Accelerated Fractionated Concurrent Chemoradiotherapy versus Conventional Chemoradiation

  2025cites this paper
• Multicentric Cross-Sectional Survey to Assess the Variation of Fractionation Strategies Used in the Management of Head and Neck Cancers in the Asian Region (INNOCENCE-ASIA)

  2025cites this paper
• Chemotherapy-free innovations in locally advanced head and neck cancer: a comprehensive review

  2025cites this paper
• Trend in Initial Management of T4 Laryngeal Squamous Cell Carcinoma

  2025cites this paper
• Long term feeding tube use in head and neck cancer survivors - a secondary analysis of patient and treatment related factors.

  2025cites this paper
• Quality assurance and reporting for FLASH clinical trials: The experience of the FEATHER trial

  2025cites this paper
• Machine learning predicting acute pain and opioid dose in radiation treated oropharyngeal cancer patients

  2025cites this paper
• State of the Art Multimodality Management of Laryngeal and Hypopharyngeal Cancers that Optimizes Survival and Function.

  2025cites this paper
• Non-surgical organ preservation and new technologies in laryngeal radiation

  2025cites this paper
• Four-Week Hypofractionated Radiotherapy for Early Glottic Cancer: A Prospective Study of Toxicity and Tolerance With Historical Comparison

  2025cites this paper
• Chemoradiotherapy vs Radiotherapy Alone in T1-2 Oropharyngeal Cancer with Low Volume Neck Disease: A Population-Based Cohort Study Utilizing the XXXXX Head and Neck Cancer Register.

  2025cites this paper
• In Regard to Margalit et al.

  2025cites this paper
• Diversity and inclusivity in oncology: A narrative review and orientation for institutional measures in Germany

  2025cites this paper
• Danish and Swedish National Data Collections for Cancer - Solutions for Radiotherapy.

  2024cites this paper
• Potentiality of Curcumin Against Radio-Chemotherapy Induced Oral Mucositis: A Review

  2024cites this paper
• A Phase I/II study evaluating the feasibility and safety of delivering adjuvant Hypofractionated radiotherapy in resected oral cavity cancers (HYPO-ART study)

  2024cites this paper
• Bibliometric analysis of laryngeal cancer treatment literature (2003–2023)

  2024cites this paper
• Human Papilloma Virus (HPV) driven oropharyngeal cancer in current or previous heavy smokers: should we look for a different treatment paradigm?

  2024cites this paper
• Extending deterministic transport capabilities for very-high and ultra-high energy electron beams

  2024cites this paper
• Radiation therapy fractionation in the modern era of head and neck oncology towards an improved therapeutic window

  2024cites this paper
• Chronic fatigue in long-term survivors of head and neck cancer treated with radiotherapy.

  2024cites this paper
• Conventional chemoradiation versus accelerated chemoradiation: A prospective study in oropharyngeal cancer

  2024influential citation
• Primary site surgical resection in cM1 oral cavity squamous cell carcinoma

  2024cites this paper
• Concomitant Boost With Six Fractions of Radiation a Week in Locally Advanced Head and Neck Cancer Patients: A Prospective Study

  2024influential citation
• Time-to-Treatment Delays and Their Prognostic Implications in Pharyngeal Cancer—An Exploratory Analysis in Western Romania

  2024cites this paper
• Acute toxicities in proton therapy for head and neck cancer – A matched analysis of the DAHANCA 35 feasibility study

  2024cites this paper
• Ways to improve the results of conservative therapy of malignant tumors of the head and neck organs. Part I. The current state of the issue (review)

  2024cites this paper
• Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline.

  2024cites this paper
• A prospective randomized comparative study to evaluate the effect of palliative hypo-fractionated radiotherapy with concurrent chemotherapy versus hypo-fractionated radiotherapy alone in advanced and unresectable head and neck cancer with no metastasis

  2023cites this paper
• A Comparison of the Toxicities in Patients With Locally Advanced Head and Neck Cancers Treated With Concomitant Boost Radiotherapy Versus Conventional Chemoradiation

  2023cites this paper
• Feasibility of Using Wearables for Home Monitoring during Radiotherapy for Head and Neck Cancer—Results from the OncoWatch 1.0 Study

  2023cites this paper
• Dose Escalation of Oropharyngeal Cancer: Long-Time Follow-Up and Side Effects

  2023cites this paper
• A comparative study of the treatment outcome of moderately accelerated radiation fractionation (with concurrent chemotherapy in daily dosing) to conventional chemo-radiotherapy in locally advanced head and neck cancers: Supportive in a resource constrained environment.

  2023cites this paper
• A proposed framework for the implementation of head and neck cancer treatment at a new cancer center from a radiation oncology perspective

  2023cites this paper
• Oropharyngeal Carcinoma with a Special Focus on HPV-Related Squamous Cell Carcinoma

  2023cites this paper
• Prognostic significance of time trends in treatment of head and neck squamous cell carcinoma.

  2023cites this paper
• Low Post-Treatment Quality of Life and the High Incidence of Pain Are Common and Significantly Exacerbated in Depressed Head and Neck Patients Treated with Definitive Accelerated Radiotherapy

  2023cites this paper
• Tumor volumes in T3 supraglottic cancers treated with radiotherapy in the modern era: A study of the Canadian Head & Neck Collaborative Research Initiative

  2023cites this paper
• Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses.

  2023cites this paper
• Importance of tumor volume, overall treatment time and fractionation sensitivity for p16-positive and p16-negative oropharyngeal tumors

  2023cites this paper
• Myoglobin-loaded gadolinium nanotexaphyrins for oxygen synergy and imaging-guided radiosensitization therapy

  2023cites this paper
• A Comparative Prospective Study Between Conventional Chemo-Radiotherapy and Pure Accelerated Radiotherapy With Concurrent Chemotherapy for the Treatment of Locally Advanced Head and Neck Cancer

  2023influential citation
• Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts

  2023cites this paper
• One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.

  2023cites this paper
• Phase I feasibility study of Olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma

  2023cites this paper
• Transoral robotic surgery for oropharyngeal cancer in the era of chemoradiation therapy.

  2022cites this paper
• How Low Can You Go? The Radiobiology of Hypofractionation.

  2022cites this paper
• Association of Primary Tumor Volume With Survival in Patients With T3 Glottic Cancer Treated With Radiotherapy: A Study of the Canadian Head & Neck Collaborative Research Initiative.

  2022cites this paper
• Prognostic and Predictive Biomarkers in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy—A Systematic Review

  2022cites this paper
• Individual elective lymph node irradiation for the reduction of complications in head and neck cancer patients (iNode): A phase-I feasibility trial protocol

  2022cites this paper
• Kurative Radiochemotherapie von Kopf-Hals-Tumoren

  2022cites this paper
• Long-term update of NRG/RTOG 0522: a randomized phase III trial of concurrent radiation and cisplatin with or without cetuximab in locoregionally advanced head and neck cancer.

  2022cites this paper
• Escalating a Biological Dose of Radiation in the Target Volume Applying Stereotactic Radiosurgery in Patients with Head and Neck Region Tumours

  2022cites this paper
• Associations between patient-reported late effects and systemic cytokines in long-term survivors of head and neck cancer treated with radiotherapy

  2022cites this paper
• Clinicopathology and Treatment Patterns of Head and Neck Cancers in Ethiopia

  2022cites this paper
• Determining the impact of COVID-19 pandemic on adjuvant therapy for oral cancer – A matched-pair analysis

  2022cites this paper
• CONCURRENT CHEMORADIOTHERAPY VERSUS ACCELERATED RADIOTHERAPY AFTER INDUCTION CHEMOTHERAPY IN INOPERABLE STAGE III NON-SMALL CELL LUNG CARCINOMA: A PROSPECTIVE COMPARATIVE STUD

  2022cites this paper
• The role of concomitant chemoradiotherapy versus radiation alone in T1-3N0 HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma.

  2022cites this paper
• Co-registration of radiotherapy planning and recurrence scans with different imaging modalities in head and neck cancer

  2022cites this paper
• Ultrasound Evaluation of Carotid Artery Intima-Media Thickness: Effective Early Marker of Carotid Artery Disease in Adult Head and Neck Cancer Patients After Neck Radiation?

  2022cites this paper
• Recurrence pattern with respect to two different dose fractionations in patients with locally advanced head and neck cancer treated with chemoradiation using image‐guided volumetric arc therapy

  2022cites this paper
• Early non-cancer mortality risk prediction after curative-intent radiotherapy or chemoradiotherapy for head and neck squamous cell carcinoma.

  2022cites this paper
• Fatigue in Patients With Head and Neck Cancer Treated With Radiation Therapy: A Prospective Study of Patient-Reported Outcomes and Their Association With Radiation Dose to the Cerebellum

  2022cites this paper
• Advances in Organ Preservation for Laryngeal Cancer

  2022cites this paper
• Larynx cancer survival model developed through open-source federated learning.

  2022cites this paper
• Compensation for radiotherapy treatment interruptions due to a cyberattack: An isoeffective DVH‐based dose compensation decision tool

  2022cites this paper
• Transfusion thresholds for guiding red blood cell transfusion.

  2021cites this paper
• Results from a prospective, randomised study on (accelerated) preoperative versus (conventional) postoperative radiotherapy in treatment of patients with resectable squamous cell carcinoma of the oral cavity - The ARTSCAN 2 study.

  2021cites this paper
• Re-Irradiation for Head and Neck Cancer: Cumulative Dose to Organs at Risk and Late Side Effects

  2021cites this paper
• Chemoradiotherapy but Not Radiotherapy Alone for Larynx Preservation in T3. Considerations from a German Observational Cohort Study

  2021cites this paper
• Prospects of accelerated fractionation chemoradiotherapy for locally advanced oropharyngeal cancer during the COVID-19 pandemic

  2021cites this paper
• The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

  2021cites this paper
• Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database

  2021cites this paper
• Treatment outcomes in patients with supraglottic laryngeal cancer: a single centre study

  2021cites this paper
• Patient-reported toxicity and quality of life profiles in head and neck cancer patients treated with definitive radiotherapy or chemoradiation.

  2021cites this paper
• SNHG17/miR-384/ELF1 axis promotes cell growth by transcriptional regulation of CTNNB1 to activate Wnt/β-catenin pathway in oral squamous cell carcinoma

  2021cites this paper
• Comprehensive toxicity risk profiling in radiation therapy for head and neck cancer: A new concept for individually optimised treatment.

  2021cites this paper
• Radiation therapy in head and neck cancer

  2021cites this paper
• Response to “Evaluation of purely accelerated six fractions per week radiotherapy in postoperative oral cavity squamous cell carcinoma”—Does it require to irradiate neck in pN0 disease?

  2021cites this paper
• Kurative Radiochemotherapie von Kopf-Hals-Tumoren

  2021cites this paper
• A multi-centre survey reveals variations in the standard treatments and treatment modifications for head and neck cancer patients during Covid-19 pandemic

  2021influential citation
• The danish head and neck cancer group (DAHANCA) 2020 radiotherapy guidelines.

  2020cites this paper
• The role of concomitant chemoradiotherapy in AJCC 7th edition T1-2N1 oropharyngeal carcinoma in the human papillomavirus era.

  2020cites this paper
• Moderately accelerated intensity‐modulated radiation therapy using simultaneous integrated boost: Practical reasons or evidence‐based choice? A critical appraisal of literature

  2020cites this paper
• Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID‐19 pandemic: The Princess Margaret experience and proposal

  2020cites this paper
• Impact of hypofractionated schemes in radiotherapy for locally advanced head and neck cancer patients

  2020cites this paper
• Most Cited Articles in Head and Neck Oncology

  2020cites this paper
• Long-Term Update of NRG Oncology RTOG 0522: A Randomized Phase III Trial of Concurrent Radiation and Cisplatin with or without Cetuximab in Locoregionally Advanced Head and Neck Cancer

  2020cites this paper
• DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity.

  2020cites this paper
• The impact of Coronavirus (COVID-19) on head and neck cancer patients’ care

  2020cites this paper
• COVID-19: Global radiation oncology’s targeted response for pandemic preparedness

  2020cites this paper
• Altered fractionation diminishes importance of tumor volume in oropharyngeal cancer: Subgroup analysis of ARTSCAN‐trial

  2020cites this paper
• Is it necessary to receive radiation for pT3-4N0 oral cancer without other adverse risk features?

  2020cites this paper
• Radiobiologically-derived bi-phasic fractionation schemes to overcome the effects of tumour hypoxia.

  2020cites this paper
• Systematic use of patient reported outcome during radiotherapy for head and neck cancer: study protocol for the national DAHANCA 38 trial

  2020cites this paper
• Durable therapeutic gain despite competing mortality in long-term follow-up of a randomized hyperfractionated radiotherapy trial for locally advanced head and neck cancer

  2020cites this paper